Health Catalyst (NASDAQ:HCAT - Get Free Report) had its price objective cut by Citigroup from $7.00 to $6.50 in a report issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Citigroup's target price points to a potential upside of 64.14% from the stock's current price.
A number of other research firms have also recently issued reports on HCAT. Stephens cut their price objective on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. Stifel Nicolaus decreased their price target on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating on the stock in a research note on Thursday, February 27th. KeyCorp cut their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Royal Bank of Canada decreased their target price on shares of Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 27th. Finally, Wells Fargo & Company reduced their price objective on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.05.
Get Our Latest Stock Report on Health Catalyst
Health Catalyst Price Performance
HCAT stock traded down $0.11 during midday trading on Friday, reaching $3.96. The company had a trading volume of 112,567 shares, compared to its average volume of 608,575. The firm has a 50-day moving average price of $4.25 and a 200-day moving average price of $6.17. The company has a market capitalization of $278.04 million, a P/E ratio of -2.93 and a beta of 1.43. Health Catalyst has a 1 year low of $3.56 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.
Insider Transactions at Health Catalyst
In other Health Catalyst news, insider Linda Llewelyn sold 6,441 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the transaction, the insider now owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Daniel Lesueur sold 16,902 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now directly owns 216,250 shares of the company's stock, valued at $977,450. This represents a 7.25 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,588 shares of company stock valued at $225,906. Company insiders own 2.50% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of HCAT. Group One Trading LLC raised its holdings in Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company's stock worth $31,000 after purchasing an additional 2,260 shares during the period. Two Sigma Securities LLC raised its stake in shares of Health Catalyst by 19.5% in the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company's stock worth $124,000 after buying an additional 2,862 shares during the period. Legato Capital Management LLC lifted its position in shares of Health Catalyst by 3.7% during the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company's stock valued at $622,000 after buying an additional 3,171 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Health Catalyst in the 4th quarter worth approximately $29,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Health Catalyst by 8.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company's stock worth $442,000 after acquiring an additional 4,798 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
See Also
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
